Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:11/7/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the second of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
7. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
8. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... Oct. 27, 2014 Pressure BioSciences, Inc. ... leader in the development and sale of high ... research market, today announced that Professor Ruedi ... accurate, highly reproducible, and robust method to allow ... protein analysis on small needle biopsy samples by ...
(Date:10/26/2014)... October 26, 2014 The report ... ADC, Network Security Equipment, WAN Optimization Appliances]: Global ... segments the data center networking market into various ... revenues. The report also identifies the factors driving ... impacting it along with the future roadmaps. , ...
(Date:10/25/2014)... 2014 ViaDerma, Inc ... devoted to bringing new products to market, is ... ViaDerma has developed an innovative, patent-pending dual carrier ... transfer of pharmaceutical active ingredients to penetrate the ... localized therapy. The transdermal delivery method also overcomes ...
(Date:10/25/2014)... October 24, 2014 DuPont Pioneer ... to more than double the acreage contracted for ... supplying its soybean crush facility in Salisbury, Md. ... program will target several markets including foodservice and ... good performance. , For the 2015 growing season, ...
Breaking Biology Technology:Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4
... Calif., July 26, 2011 Synterra Energy, Inc. ... and assets for waste biomass conversion from Pacific ... Lion Bio-Energy (Toledo, Ohio).  With the merger, Synterra ... bio-refineries for the economic production of renewable fuels, ...
... 26, 2011   At the ... Center for Devices and Radiologic Health of the United States ... Thursday July 21 in Gaithersburg, Maryland to review the results ... charge of the panel was to review the clinical data ...
... Neogen Corporation (NASDAQ: NEOG ) announced today that ... 31, increased 30% from the previous year to $22,839,000. Net ... compared to the prior year,s $0.76 per share. ... up from $140,509,000 in the company,s previous fiscal year. Both ...
Cached Biology Technology:Synterra Energy Merges Key Technologies to Commercialize Next Generation Integrated Bio-refinery 2FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States 2FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States 3FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States 4Neogen Reports 30% Increase in Net Income 2Neogen Reports 30% Increase in Net Income 3Neogen Reports 30% Increase in Net Income 4Neogen Reports 30% Increase in Net Income 5
(Date:10/29/2014)... decompose, their types and numbers of bugs and ... mean the difference between a closed case and ... using a more than $866,000 U.S. Department of ... these changing populations. The microbial communities may provide ... gender, race, socioeconomic relations and more, said Eric ...
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
(Date:10/29/2014)... Ghrelin is a hormone released by the stomach and ... viewed as a psychoactive substance that primarily affects brain ... , This knowledge, combined with findings from animal ... the potential to stimulate alcohol craving. , Dr. Lorenzo ... found that, as they had anticipated, alcohol craving was ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2
... CA) Researchers at the Burnham Institute for Medical Research ... intestinal protein leakage in mice, allowing the team to ... in an in vivo setting. Protein-losing enteropathy (PLE) encompasses ... into the digestive tract. One type of PLE ...
... the Hinode mission have shed new light on the Sun,s ... disrupt power grids, satellites and communications on Earth. The ... journal Science. , Data from Hinode, a Japanese (JAXA) mission ... role in driving the solar wind into space. The solar ...
... new and compelling argument for reducing fish harvests the ... short-term pain of lower catches for the long-term gain of ... ground-breaking study on fisheries over-exploitation. They say their findings, ... a key cause of over-fishing industry opposition to lower ...
Cached Biology News:Safe and effective therapy discovered for patients with protein-losing enteropathy 2Hinode: new insights on the origin of solar wind 2Economists: Reduce fish catch now for bigger net profits later 2Economists: Reduce fish catch now for bigger net profits later 3
... DNase is a preparation of deoxyribonuclease ... DNA to produce 3-hydroxyl oligonucleotides. This ... applications where maintaining the integrity of ... qualified for use with the Core ...
... Type Liquid. In 100 mM KCl, ... EDTA, 20% glycerol, pH 7.9. AVOID FREEZE/THAW CYCLES. ... monomeric protein of 765 amino acids encoded by ... both positive and negative supercoiled DNAs without the ...
Request Info...
... III digests duplex DNA in a 3'-> ... or nick, producing stretches of single-stranded DNA. ... Exonuclease III proceeds at a uniform rate ... rate of exonucleolytic excision of deoxyribonucleotides by ...
Biology Products: